About Contact Us Careers

Dendritic Cell Therapy Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2546
Published Date: Oct 15, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Dendritic Cell Cancer Vaccine Landscape

Kite Pharma
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Argos Therapeutics
Dendreon
GlaxoSmithKline
Batavia Biosciences
ImmunoCellular Therapeutics Ltd.
Elios Therapeutics
Merck & Co.
Tella Incorporation

Browse Key Market Insights with Data Illustration:

Dendritic Cell Cancer Vaccine Market Size & Share, Forecast Report 2036

In the News

April 15, 2020: Immutep and Batavia Biosciences developed high yielding cell line for LAG-3 (Lymphocyte Activation Gene- 3) immunotherapy for autoimmune diseases. Further, the preclinical development of compound took place. These clinical tests are taking place to observe the effectiveness of the treatment.

Author Credits: Radhika Pawar

Report ID: 2546
Published Date: Oct 15, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of dendritic cell cancer vaccine is evaluated at USD 714.41 million.

Dendritic Cell Cancer Vaccine Market size was over USD 651.36 million in 2023 and is poised to exceed USD 2.87 billion by 2036, growing at over 12.1% CAGR during the forecast period i.e., between 2024-2036.

North America industry is likely to hold largest revenue share by 2036, as people in the region are more aware and the diagnosis techniques are supreme in these areas.

The major players in the market are Kite Pharma, Argos Therapeutics, Dendreon, GlaxoSmithKline, Batavia Biosciences, ImmunoCellular Therapeutics Ltd., Elios Therapeutics, Merck & Co., Tella Incorporation, and others.

Inquiry Before Buying Request Free Sample